Drug Profile
Research programme: dual aurora/FLT kinase inhibitors - Sareum
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Sareum
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Haematological malignancies
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in United Kingdom
- 28 Nov 2020 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in China
- 26 Oct 2018 Dual aurora/FLT kinase inhibitors is still in preclinical trials for Haematological malignancies in United Kingdom